Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Mites SCIT in Moderate to Severe House Dust Mite Allergic Rhinitis/Rhinoconjunctivitis
2023-504942-75-01Phase 3Completed
- Sponsor
- HAL Allergy Group
- Start
- Jan 2024
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma comparing PURETHAL Mites SCIT with Placebo SCIT (2 arms). Primary endpoint: Average daily TCRS during the last 8 weeks of treatment. Started Jan 2024; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2023-504942-75-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504942-75-01.